CClinicalTrials.gg
CompletedNCT02034487Updated Jan 13, 2014

Delayed Puberty in Boys; Clinical and Biochemical Characteristics and Effect of Testosterone Treatment

An observational study in Delayed Puberty, sponsored by Rigshospitalet, Denmark. Completed at 1 site in Denmark. Open to male participants aged 13 Years to 20 Years. Per ClinicalTrials.gov, last updated 2014-01-13.

Sponsored by Rigshospitalet, Denmark · Observational

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
451
Ages
13 Years to 20 Years
Sex
Male
01

Study summary

To evaluate the phenotype and biochemical characteristics of boys referred for delayed puberty, to describe the frequency of associated co-morbidities and diseases, to evaluate the diagnostic criteria and the effect of testosterone treatment.

Read the detailed description

Delayed Puberty in Boys; Clinical and biochemical characteristics and effect of testosterone treatment, is a retrospective study in a large case series of Danish boys with delayed puberty.

All boys were referred to the Department of Growth and Reproduction to be evaluated for delayed puberty.

Medical history: Birth length, birth weight, gestational age at birth, medical history (including cryptorchidism and hypospadias), family history of delayed puberty in mother, father and possible siblings.

Physical examination: Pubertal staging according to Tanners classification of boys, genitalia development (G1-G5), pubic hair development (PH1-PH6), axillary hair (yes/no), axillary sweat (yes/no), gynecomastia (yes/no), micropenis (yes/no), height, mother height, father height, target height, weight, BMI, bone age and predicted adult height.

Blood sampling for measurement of hormone levels: Follicle stimulating hormone (FSH), luteinizing hormone (LH), estradiol, anti-mullerian hormone, sex hormone-binding globulin, testosterone, dehydroepiandrosterone-sulfate, androstenedione, inhibin A, inhibin B, growth hormone, insulin like growth factor-1 and insulin like growth factor binding protein-3.

Gonadotropin-releasing hormone stimulation test for measurement of peak FSH and peak LH.

Retrospective DNA analysis looking for common polymorphisms.

If testosterone treatment were initiated, route of administration, dose and duration of treatment were registered.

02

Conditions studied

  • Delayed Puberty

Keywords

  • Delayed Puberty
  • Boys
  • Hormones
  • Polymorphism, Genetic
03

In context

Lead sponsor

Rigshospitalet, Denmark is the lead sponsor of 1,017 studies on the registry; 183 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
13 Years to 20 Years
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consisted of boys who were referred to be evaluated for delayed puberty at the Department of Growth and Reproduction between January 1990 and February 2013.

Inclusion criteria

  • All boys identified in the period from January 1990 to February 2013

Exclusion criteria

Exclusion Criteria:

  • Misclassified (other diagnoses)
  • Insufficient data
  • Lost to follow up
05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
451 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Boys with delayed puberty

    Boys with no signs of puberty by an age that is -2 standard deviation below the population mean.

    Other: retrospective data collection

Interventions

  • Otherretrospective data collection
06

What researchers measure

Primary outcomes

  1. Age at diagnosis in boys with delayed puberty.

    We will evaluate the mean age at diagnosis as well as the age distribution of newly diagnosed boys. These data are compared to age at onset and progression of normal puberty in contemporary healthy Danish boys.

    Time frame: At first evaluation

Secondary outcomes

  1. Selected secondary outcomes include clinical, auxological and biochemical parameters and association to specific genetic polymorphisms

    Specifically, genital stage, pubic hair stage, axillary hair, axillary sweat, gynecomastia, micropenis, height, mother height, father height, target height, weight, BMI, bone age and predicted adult height. We will evaluate serum levels of follicle stimulating hormone, luteinizing hormone, estradiol, anti-mullerian hormone, sex hormone-binding globulin, testosterone, dehydroepiandrosterone-sulfate, androstenedione, inhibin A, inhibin B, growth hormone, insulin like growth factor-1 and insulin like growth factor binding protein-3. We will evaluate the effect of candidate polymorphisms suspected to affect pubertal timing, e.g. FSHR, FSHB, FGF23, KISS1, NeurokininB, GnRH, GnRH-R, LH, LH-R, GHRd3.

    Time frame: At first evaluation and during first 12 months of observation / treatment

07

Study locations

1 site
  • Department of Growth and Reproduction, Rigshospitalet
    Copenhagen, 2100, Denmark
08

References and documents

Publications

  • Lawaetz JG, Hagen CP, Mieritz MG, Blomberg Jensen M, Petersen JH, Juul A. Evaluation of 451 Danish boys with delayed puberty: diagnostic use of a new puberty nomogram and effects of oral testosterone therapy. J Clin Endocrinol Metab. 2015 Apr;100(4):1376-85. doi: 10.1210/jc.2014-3631. Epub 2015 Jan 16. PubMed 25594861 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 13, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02034487
Lead sponsor
Rigshospitalet, Denmark
Responsible party
Anders Juul (PhD, DMSc, Rigshospitalet, Denmark) — Principal investigator
First posted
Jan 13, 2014
Start date
Jan 1990
Primary completion
Feb 2013
Completion
Oct 2013
Last update
Jan 13, 2014

Study contacts

Anders Juul, PhD, DMSc
principal investigator · Rigshospitalet, Denmark
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion